Development of therapeutic agents for neurodegenerative disease through improvement of phagocytosis through NCKAP1 regulation
Opportunity ContactJames Noh, CEOSeoul, South Korea Hanyang University Website Pharmalicensing.com Development of customized treatments for neurodegenerative disease focused on immune-inflammatory modulation through novel use of NCKAP1 in the regulation of microglial cell
